Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy.

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Bristol Myers Squibb has a robust pipeline with plenty of active programs, and its outlook for the next decade remains strong ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak revenue expectations. Learn more about BMY stock here.

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

Bristol Myers Squibb’s (NYSE: BMY) financial results haven’t been great lately. Its third-quarter revenue of $12.2 billion was an increase of only 3% year over year. To make matters worse, over the ...